NIH/NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1)

The National Cancer Institute (NCI) seeks to support an experimental therapeutics clinical trials program through the creation of a consolidated, integrated, NCI Experimental Therapeutics-Clinical Trials Network (ET-CTN).

This FOA solicits UM1 cooperative agreement applications for multidisciplinary groups that will conduct early phase experimental therapeutics clinical trials. Members of the ET-CTN will work with agent-specific, trans-network investigational teams for two broad purposes: (1) to define the drug development plan, and (2) to conduct clinical trials to support Investigational New Drug (IND) applications by NCI’s Cancer Therapy Evaluation Program (CTEP) in the Division of Cancer Treatment and Diagnosis (DCTD).

The ultimate purpose of the ET-CTN is to define better approaches to the development of novel anticancer agents that capitalize on the ability to characterize tumors molecularly, and to find appropriate biomarkers to select patients most likely to respond to specific agents. The clinical trials to be conducted by the ET-CTN are intended to provide the dose, schedule, and early evidence of activity that will help guide disease-specific clinical trials to be conducted by the National Clinical Trials Network (NCTN), which will focus on controlled, randomized, Phase 3 trials.

This is a limited submission opportunity; the University may submit only one (1) grant application. Interested faculty must submit an abstract, CV, and budget to Dean Puzas (Catherine_muzytchuk@urmc.rochester.edu) by March 1, 2013. Please use the words “Experimental Therapeutics” in the subject line. The Deans will choose a candidate by March 9, 2013.

The complete program solicitation can be found here.  

The Letter of Intent is due March 23, 2013. The full proposal is due August 23, 2013. It is important to remember that ORPA must receive electronic proposals five (5) business days prior to the sponsor’s deadline, along with a completed and signed University sign-off form.

 

NIH Funding Acknowledgement ** Important ** All publications resulting from the utilization of CTSI resources are required to credit the CTSI grant by including the NIH FUNDING ACKNOWLEDGEMENT and must comply with the NIH Public Access Policy.